Invesco Ltd. Alkermes Plc. Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Alkermes Plc. stock. As of the latest transaction made, Invesco Ltd. holds 584,293 shares of ALKS stock, worth $17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

584,293

Previous 613,023 4.69%

Holding current value

$17 Million

Previous $17.5 Million 0.06%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$26.13 - $30.46 $750,714 - $875,115	-28,730 Reduced 4.69%	584,293 $17.5 Million
Q2 2025 Aug 13, 2025	SELL	$26.59 - $32.65 $3.26 Million - $4 Million	-122,473 Reduced 16.65%	613,023 $17.5 Million
Q1 2025 May 12, 2025	BUY	$28.08 - $36.0 $381,326 - $488,880	13,580 Added 1.88%	735,496 $24.3 Million
Q4 2024 Feb 13, 2025	SELL	$25.7 - $31.46 $749,617 - $917,625	-29,168 Reduced 3.88%	721,916 $20.8 Million
Q3 2024 Nov 12, 2024	BUY	$23.01 - $28.55 $1.26 Million - $1.57 Million	54,844 Added 7.88%	751,084 $21 Million

Q2 2024 Aug 13, 2024	BUY	$23.21 - $27.24 $2.23 Million - $2.61 Million	95,937 Added 15.98%	696,240 $16.8 Million
Q1 2024 May 14, 2024	SELL	$26.4 - $32.56 $6.59 Million - $8.13 Million	-249,685 Reduced 29.38%	600,303 $16.3 Million
Q4 2023 Feb 12, 2024	BUY	$23.37 - $28.68 $10.7 Million - $13.1 Million	457,122 Added 116.36%	849,988 $23.6 Million
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $227,575 - $267,780	-8,376 Reduced 2.09%	392,866 $11 Million
Q2 2023 Aug 11, 2023	SELL	$28.34 - $33.63 $794,965 - $943,355	-28,051 Reduced 6.53%	401,242 $12.6 Million
Q1 2023 May 12, 2023	SELL	$25.31 - $29.02 $1.15 Million - $1.31 Million	-45,243 Reduced 9.53%	429,293 $12.1 Million
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $518,332 - $619,920	23,625 Added 5.24%	474,536 $12.4 Million
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $2.64 Million - $3.82 Million	-119,881 Reduced 21.0%	450,911 $10.1 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $719,162 - $831,940	27,241 Added 5.01%	570,792 $17 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $706,472 - $857,137	30,623 Added 5.97%	543,551 $14.3 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $1.52 Million - $2.28 Million	70,924 Added 16.05%	512,928 $11.9 Million
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $7.72 Million - $10.6 Million	-330,477 Reduced 42.78%	442,004 $13.6 Million
Q2 2021 Aug 17, 2021	BUY	$18.78 - $25.15 $73,749 - $98,764	3,927 Added 0.51%	772,481 $18.9 Million
Q1 2021 May 17, 2021	BUY	$18.21 - $23.2 $2.92 Million - $3.73 Million	160,576 Added 26.41%	768,554 $14.4 Million
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $161,317 - $231,652	10,482 Added 1.75%	607,978 $12.1 Million
Q3 2020 Nov 16, 2020	BUY	$16.16 - $20.66 $5.92 Million - $7.57 Million	366,528 Added 158.69%	597,496 $9.9 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $4.51 Million - $6.57 Million	-338,537 Reduced 59.44%	230,968 $4.48 Million
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $4.94 Million - $8.04 Million	378,556 Added 198.25%	569,505 $8.21 Million
Q4 2019 Feb 14, 2020	SELL	$17.29 - $21.74 $3.42 Million - $4.3 Million	-197,728 Reduced 50.87%	190,949 $3.9 Million
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $344,273 - $428,444	17,646 Added 4.76%	388,677 $7.58 Million
Q2 2019 Aug 14, 2019	SELL	$21.47 - $37.33 $85.2 Million - $148 Million	-3,967,433 Reduced 91.45%	371,031 $8.36 Million
Q1 2019 May 15, 2019	SELL	$28.4 - $36.49 $250,800 - $322,243	-8,831 Reduced 0.2%	4,338,464 $158 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $121 Million - $194 Million	4,347,295 New	4,347,295 $128 Million

Others Institutions Holding ALKS

# of Institutions

400

Shares Held

176M

Call Options Held

901K

Put Options Held

400K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.77B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account